ENTITY
Celltrion Inc

Celltrion Inc (068270 KS)

564
Analysis
Health CareSouth Korea
Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment
more
bullishCelltrion Inc
26 Feb 2025 08:30

Celltrion (068270 KS): Record High Sales in 4Q; Sequentially Weaker Profit; Solid Outlook for 2025

​Celltrion reported 178% revenue growth in 4Q24. The company guided for 2025 revenue of KRW5.0T, up 43% YoY. Operating profit margin is expected to...

Logo
304 Views
Share
bullishCelltrion Inc
13 Dec 2024 19:06

Celltrion: Meaningful Increase in Cash and Stock Dividends

Celltrion Inc announced meaningful increase in dividends. Celltrion will pay out stock dividend of 0.05 for shareholders as of record in 2024 (up...

Logo
485 Views
Share
bullishCelltrion Inc
13 Dec 2024 17:09

Celltrion Inc (068270 KS): Record High Sales in 3Q; Pipeline Progress Entails Long-Term Growth

Celltrion has announced dividend of KRW750 per share and one bonus shares for every 20 shares held. The record date for dividend payment and bonus...

Logo
702 Views
Share
28 Mar 2025 05:29

Korea: Short Selling Is Back in March; Trade Ideas

Short selling in Korea commences from Monday. There will be a lot of interest in shorting stocks/sectors depending on how they have performed since...

Logo
1.5k Views
Share
bearishCelltrion Inc
17 Sep 2024 17:14

Celltrion Inc (068270 KS)– Is the Sell-Side’s Bullishness Justified?

Biosimilar market is expected to grow much faster than generic drug market, but profitability will be a challenge. Celltrion’s guidance is too...

Logo
daaimon
364 Views
Share
x